Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026338 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
A Phase 3 study of Pancreatic Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
- 20
- Study locations
NCT00026338: Completed Phase 3 study of Pancreatic Cancer, sponsored by NCIC Clinical Trials Group.
NCT00026338 is a Phase 3 study of Pancreatic Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 569 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026338, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG erlotinib hydrochloride
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- Sutter Health West Cancer Research Group - Greenbrae
- Loma Linda University Cancer Institute - Loma Linda
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Kenmar Research Institute - Los Angeles
- Century City Hospital - Los Angeles
- David Geffen School of Medicine - Los Angeles
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
Florida
- Florida Cancer Specialists - Fort Myers
- Oncology-Hematology Group of South Florida - Miami
- Ocala Oncology Center - Ocala
- Oncology & Hematology Associates of West Broward - Tamarac
- Moffitt Clinic at Tampa General Hospital - Tampa
Connecticut
- Davis, Posteraro, & Wasser, MDs, LLP - Manchester
- New Britain General Hospital - New Britain
- Eastern Connecticut Hematology and Oncology Associates - Norwich
- Hematology Oncology, P.C. - Stamford
Arizona
- Arizona Clinical Research Center - Tucson
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Central Georgia Hematology Oncology, P.C. - Macon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2001-10-29 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 3 |
What the finished NCT00026338 record still lists
NCT00026338 is an interventional study that assigns participants to a tested intervention. The registered 569 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00026338 names 20 study sites across 6 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00026338 about?
NCT00026338 is a clinical study titled "Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill ...
What is the current status of trial NCT00026338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2001-10-29. Estimated completion is 2009-02-10.
What conditions does trial NCT00026338 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00026338?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00026338?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026338 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00026338's enrollment target sits among peer trials
569 25th of 278 higher than 253 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
- NCT07266831 · 570 participants · Phase 2
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI